logo

Soligenix, Inc. (SNGX)



Trade SNGX now with
  Date
  Headline
8/13/2019 7:23:52 AM Soligenix Q2 Basic Net Loss $2.1 Mln Or $0.12 Per Share
5/14/2019 7:07:51 AM Soligenix Q1 Basic Net Loss $1.6 Mln Or $0.09/shr Vs. Loss $2.4 Mln Or $0.27/shr Prior Year
4/23/2019 7:09:53 AM Soligenix Says Advances Development Of Heat Stable Ricin Toxin Vaccine-RiVax
4/4/2019 7:01:29 AM Soligenix Receives US Patent For Dusquetide Related Analogs
3/26/2019 7:07:56 AM Soligenix Says Actively Enrolling Patients In Phase 3 Clinical Trial Of SGX942
1/23/2019 6:02:06 AM Soligenix Secures European Patent For Dusquetide And Related Innate Defense Regulator Analogs
11/9/2018 6:05:58 AM Soligenix Q3 Net Loss $1.9 Mln Or $0.11/shr Vs. Net Loss $1.0 Mln Or $0.17/shr Last Year
10/4/2018 6:11:56 AM Soligenix Reports Poster Presentations Of Its Ricin Vaccine And Dusquetide Oral Mucositis Programs
9/4/2018 6:08:27 AM Soligenix Reports Publication Of Extended Stability Studies For RiVax
8/22/2018 6:05:18 AM Soligenix Receives US Patent For Improved Production Of Synthetic Hypericin
8/8/2018 6:13:58 AM Soligenix Q2 Basic Net Loss $1.6 Mln Or $0.18 Per Share
7/24/2018 6:03:08 AM Soligenix Appoints Mark Pearson To Board
6/28/2018 6:02:00 AM Soligenix Prices Public Offering Of 7.77 Mln Shares And Warrants To Purchase 3.11 Mln Shares
5/11/2018 6:05:53 AM Soligenix Q1 Net Loss $2.4 Mln Or $0.27/Shr